{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:16Z","timestamp":1792197316691,"version":"4.4.0"},"reference-count":224,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oncolytic viruses represent a paradigm-shifting approach to cancer immunotherapy, functioning as in situ vaccines that convert immunologically \u201ccold\u201d tumors into \u201chot\u201d tumors through induction of immunogenic cell death (ICD). Despite the clinical success of checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)\/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), many patients exhibit primary or acquired resistance due to insufficient tumor immunogenicity and exclusion of tumor-infiltrating lymphocytes. Oncolytic viruses address this limitation by selectively replicating in tumor cells, inducing robust ICD characterized by four cardinal hallmarks: calreticulin exposure, ATP secretion, HMGB1 release, and type I interferon production. This review systematically examines the molecular mechanisms underlying virus-induced ICD, compares DNA virus platforms (Vaccinia, HSV-1, Adenovirus) with RNA virus platforms (Coxsackieviruses A21, A11, and B3), and analyzes clinical trial data demonstrating synergistic efficacy when combined with checkpoint inhibitors. Notably, RNA viruses generate higher type I interferon responses compared to DNA viruses, correlating with superior clinical outcomes. Coxsackievirus A21 combined with pembrolizumab achieved a 47% objective response rate in melanoma in the CAPRA trial, representing notable efficacy exceeding either monotherapy. Coxsackievirus A11 demonstrates exceptional selectivity for thoracic cancers through ICAM-1-dependent receptor tropism and potent immunogenic cell death induction. Japanese researchers have pioneered microRNA-targeted Coxsackievirus B3, achieving cardiac safety attenuation while preserving complete oncolytic potency and ICD-inducing capacity. This comprehensive analysis synthesizes molecular mechanisms, platform comparisons, clinical efficacy data, and translational challenges to guide future development of oncolytic virotherapy as a cornerstone of cancer immunotherapy.<\/jats:p>","DOI":"10.3390\/v18040461","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:19:14Z","timestamp":1776075554000},"page":"461","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-8797","authenticated-orcid":false,"given":"Hiroyuki","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: Mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_15","first-page":"659","article-title":"Oncolytic viruses: A renaissance in cancer therapy","volume":"12","author":"Pol","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","article-title":"Oncolytic virotherapy: A contest between apples and oranges","volume":"25","author":"Russell","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrmicro3140","article-title":"New viruses for cancer therapy: Meeting clinical needs","volume":"12","author":"Miest","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/cdd.2013.84","article-title":"Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments","volume":"21","author":"Inoue","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.2147\/OTT.S115245","article-title":"Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB\/C and IVM1a melanoma: Subanalysis of the Phase III OPTiM trial","volume":"9","author":"Harrington","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","article-title":"Armed oncolytic viruses: A kick-start for anti-tumor immunity","volume":"41","author":"Fouchier","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral immunotherapy-update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41590-019-0556-1","article-title":"Regulation of cGAS- and RLR-mediated immunity to nucleic acids","volume":"21","author":"Ablasser","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: Their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/cdd.2008.67","article-title":"The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death","volume":"15","author":"Panaretakis","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.4161\/auto.25399","article-title":"ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death","volume":"9","author":"Garg","year":"2013","journal-title":"Autophagy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/cdd.2012.74","article-title":"PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress","volume":"19","author":"Verfaillie","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.it.2012.08.002","article-title":"Calreticulin in the immune system: Ins and outs","volume":"34","author":"Raghavan","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/onc.2010.500","article-title":"Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress","volume":"30","author":"Martins","year":"2011","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.1208347","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1721810","DOI":"10.1080\/2162402X.2020.1721810","article-title":"PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models","volume":"9","author":"Yamazaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nature09413","article-title":"Pannexin 1 channels mediate \u2018find-me\u2019 signal release and membrane permeability during apoptosis","volume":"467","author":"Chekeni","year":"2010","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2008.05.013","article-title":"Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein","volume":"29","author":"Kazama","year":"2008","journal-title":"Immunity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","volume":"18","author":"Sarti","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nature13085","article-title":"Nucleotide signalling during inflammation","volume":"509","author":"Idzko","year":"2014","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1073\/pnas.1003893107","article-title":"A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.2119\/molmed.2015.00087","article-title":"High Mobility Group Box Protein 1 (HMGB1): The prototypical endogenous danger molecule","volume":"21","author":"Yang","year":"2015","journal-title":"Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1084\/jem.20120189","article-title":"Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release","volume":"209","author":"Venereau","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/cdd.2013.72","article-title":"Defective immunogenic cell death of HMGB1-deficient tumors: Compensatory therapy with TLR4 agonists","volume":"21","author":"Yamazaki","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","article-title":"HMGB1 and RAGE in inflammation and cancer","volume":"28","author":"Sims","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I interferon in chronic virus infection and cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gewaid, H., and Bowie, A.G. (2024). Regulation of type I and type III interferon induction in response to pathogen sensing. Curr. Opin. Immunol., 87.","DOI":"10.1016\/j.coi.2024.102424"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Dai, J., Zhou, P., Li, S., and Qiu, H. (2022). New Insights into the Crosstalk among the Interferon and Inflammatory Signaling Pathways in Response to Viral Infections: Defense or Homeostasis. Viruses, 14.","DOI":"10.3390\/v14122798"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: A renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Garg, A.D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R.B., Bravo-San Pedro, J.M., Breckpot, K., Brough, D., Chaurio, R., and Cirone, M. (2015). Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00588"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","article-title":"Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity","volume":"81","author":"Symons","year":"1995","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1128\/JVI.74.23.11230-11239.2000","article-title":"The vaccinia virus soluble alpha\/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN","volume":"74","author":"Symons","year":"2000","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1073\/pnas.89.11.4825","article-title":"The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase","volume":"89","author":"Chang","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.2173860","article-title":"Mapping of herpes simplex virus-1 neurovirulence to \u03b3134.5, a gene nonessential for growth in culture","volume":"250","author":"Chou","year":"1990","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1128\/JVI.72.11.8620-8626.1998","article-title":"The herpes simplex virus US11 protein effectively compensates for the \u03b31(34.5) gene if present before activation of protein kinase R by precluding its activation","volume":"72","author":"Cassady","year":"1998","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: Biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat. Med."},{"key":"ref_96","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/317813a0","article-title":"Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype","volume":"317","author":"Buller","year":"1985","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/jnci\/91.20.1744","article-title":"Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases","volume":"91","author":"Gnant","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","article-title":"Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma","volume":"6","author":"Mastrangelo","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2011.558838","article-title":"Oncolytic vaccinia virus for the treatment of cancer","volume":"11","author":"Guse","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI32727","article-title":"Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963","volume":"117","author":"Thorne","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.surg.2007.09.017","article-title":"Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus","volume":"142","author":"Lin","year":"2007","journal-title":"Surgery"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1089\/hum.2008.036","article-title":"Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma","volume":"19","author":"Kelly","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cgt.2008.87","article-title":"Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: Preclinical development of a therapeutic agent","volume":"16","author":"Gentschev","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers","volume":"24","author":"Guo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/ncomms7410","article-title":"Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing","volume":"6","author":"Arulanandam","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e009302","DOI":"10.1136\/jitc-2024-009302","article-title":"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment","volume":"12","author":"Azar","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Wei, M., Zuo, S., Chen, Z., Qian, P., Zhang, Y., Kong, L., Gao, H., Wei, J., and Dong, J. (2022). Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. Front Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017574"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"eaax7992","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of Western Reserve strain oncolytic vaccinia virus: Safety, systemic spread, and antitumor activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00262-017-1967-1","article-title":"Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors","volume":"66","author":"Dummer","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"226ra232","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_124","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Chin. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Macarulla","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.urology.2005.02.033","article-title":"Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer","volume":"66","author":"Matsumoto","year":"2005","journal-title":"Urology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0090-4295(02)01748-X","article-title":"Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer","volume":"60","author":"Sachs","year":"2002","journal-title":"Urology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","article-title":"Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21","volume":"10","author":"Shafren","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_133","first-page":"1471","article-title":"Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21","volume":"26","author":"Au","year":"2005","journal-title":"Int. J. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ijc.20866","article-title":"Oncolysis of human ovarian cancers by echovirus type 1","volume":"115","author":"Shafren","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/jvi.71.6.4736-4743.1997","article-title":"Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry","volume":"71","author":"Shafren","year":"1997","journal-title":"J. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","article-title":"Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21","volume":"113","author":"Skelding","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0891-5849(00)00223-9","article-title":"Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades","volume":"28","author":"Hubbard","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.surg.2007.01.016","article-title":"ICAM-1 expression determines malignant potential of cancer","volume":"141","author":"Roland","year":"2007","journal-title":"Surgery"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ijc.28066","article-title":"Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage\/cancer cell adhesion","volume":"133","author":"Usami","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00262-022-03314-1","article-title":"A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: Results from the CAPRA study","volume":"72","author":"Silk","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e005224","DOI":"10.1136\/jitc-2022-005224","article-title":"Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study","volume":"10","author":"Curti","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/s41598-023-33126-x","article-title":"Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer","volume":"13","author":"Sakamoto","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.21873\/anticanres.12963","article-title":"A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11","volume":"38","author":"Wang","year":"2018","journal-title":"Anticancer. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/cas.15645","article-title":"Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma","volume":"114","author":"Okamura","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"15191","DOI":"10.1073\/pnas.261452898","article-title":"The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction","volume":"98","author":"Cohen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(02)00912-1","article-title":"Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape","volume":"110","author":"Walters","year":"2002","journal-title":"Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","article-title":"HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses","volume":"94","author":"Tomko","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","first-page":"2088","article-title":"Inhibition of the Raf\/MEK\/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells","volume":"63","author":"Anders","year":"2003","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2013.509","article-title":"Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: A multitumour array analysis","volume":"109","author":"Bockhorn","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/dmrr.1255","article-title":"Enteroviruses and type 1 diabetes","volume":"27","author":"Tracy","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/01.CIR.99.10.1348","article-title":"Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction","volume":"99","author":"Pauschinger","year":"1999","journal-title":"Circulation"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/vim.2006.19.133","article-title":"Coxsackievirus myocarditis: Interplay between virus and host in the pathogenesis of heart disease","volume":"19","author":"Tam","year":"2006","journal-title":"Viral Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/BOR.0b013e328353372d","article-title":"Update on coxsackievirus B3 myocarditis","volume":"24","author":"Fairweather","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/CIRCGENETICS.110.957415","article-title":"Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease","volume":"3","author":"Corsten","year":"2010","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathmechdis.3.121806.151534","article-title":"Molecular biology and pathogenesis of viral myocarditis","volume":"3","author":"Esfandiarei","year":"2008","journal-title":"Annu. Rev. Pathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ng1725","article-title":"The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation","volume":"38","author":"Chen","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0960-9822(02)00809-6","article-title":"Identification of tissue-specific microRNAs from mouse","volume":"12","author":"Rauhut","year":"2002","journal-title":"Curr. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1126\/science.1139089","article-title":"Control of stress-dependent cardiac growth and gene expression by a microRNA","volume":"316","author":"Sutherland","year":"2007","journal-title":"Science"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2007.03.030","article-title":"Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2","volume":"129","author":"Zhao","year":"2007","journal-title":"Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1101\/gad.1738708","article-title":"microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart","volume":"22","author":"Liu","year":"2008","journal-title":"Genes Dev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm.1776","article-title":"Engineering microRNA responsiveness to decrease virus pathogenicity","volume":"14","author":"Kelly","year":"2008","journal-title":"Nat. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.chom.2008.08.003","article-title":"Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines","volume":"4","author":"Barnes","year":"2008","journal-title":"Cell Host Microbe"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1128\/JVI.01788-09","article-title":"Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting","volume":"84","author":"Kelly","year":"2010","journal-title":"J. Virol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21873\/anticanres.14753","article-title":"Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3","volume":"41","author":"Sagara","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/mt.2011.55","article-title":"MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism","volume":"19","author":"Leber","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-med-050715-104655","article-title":"Recombinant Poliovirus for Cancer Immunotherapy","volume":"69","author":"Gromeier","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"eaan4220","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs","volume":"9","author":"Brown","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_173","first-page":"493","article-title":"Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment","volume":"19","author":"Hardcastle","year":"2017","journal-title":"Neuro-Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/mt.2009.218","article-title":"Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter","volume":"17","author":"Msaouel","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I\/IIa Glioblastoma Trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Angelova, A.L., Barf, M., Geletneky, K., Unterberg, A., and Rommelaere, J. (2017). Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. Viruses, 9.","DOI":"10.3390\/v9120382"},{"key":"ref_179","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Moglan, A.M., Albaradie, O.A., Alsayegh, F.F., Alharbi, H.M., Samman, Y.M., Jalal, M.M., Saeedi, N.H., Mahmoud, A.B., and Alkayyal, A.A. (2023). Preclinical efficacy of oncolytic VSV-IFNbeta in treating cancer: A systematic review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1085940"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1517\/14712598.2015.1088000","article-title":"Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance","volume":"15","author":"Schirrmacher","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: Future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapanagiotou","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: The phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e001621","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: Findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e013818","DOI":"10.1136\/jitc-2025-013818","article-title":"Oncolytic virus OH2 induces PD-L1 upregulation via NF-kappaB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system","volume":"14","author":"Xu","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1158\/1078-0432.CCR-09-0796","article-title":"Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma","volume":"15","author":"Pandha","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Berry","year":"2008","journal-title":"Prostate"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"107264","DOI":"10.1016\/j.lungcan.2023.107264","article-title":"Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors","volume":"181","author":"Tsutsumi","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2009.135","article-title":"The case of oncolytic viruses versus the immune system: Waiting on the judgment of Solomon","volume":"20","author":"Prestwich","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.virol.2011.11.014","article-title":"Early infection and spread of a conditionally replicating adenovirus under conditions of plaque formation","volume":"423","author":"Hofacre","year":"2012","journal-title":"Virology"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","article-title":"Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant","volume":"7","author":"Puhlmann","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: Priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Pettigrew","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.07.005","article-title":"Engineering and combining oncolytic measles virus for cancer therapy","volume":"56","author":"Leber","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/mt.2010.189","article-title":"The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis","volume":"18","author":"Heinemann","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e000710","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e003923","DOI":"10.1136\/jitc-2021-003923","article-title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","volume":"10","author":"Nelson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"102151","DOI":"10.1016\/j.tranon.2024.102151","article-title":"Oncolytic vaccinia virus armed with 4-1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1\/PD-L1 blockade in a pancreatic cancer model","volume":"50","author":"Ju","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Vitale, M., Scialo, F., Passariello, M., Leggiero, E., D\u2019Agostino, A., Tripodi, L., Gentile, L., Bianco, A., Castaldo, G., and Cerullo, V. (2022). Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. Front Oncol., 12.","DOI":"10.3389\/fonc.2022.902190"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e008431","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/mt.2008.130","article-title":"A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication","volume":"16","author":"Edge","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nbt.1542","article-title":"MicroRNA-mediated species-specific attenuation of influenza A virus","volume":"27","author":"Perez","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"102786","DOI":"10.1016\/j.ebiom.2020.102786","article-title":"Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses","volume":"56","author":"Raimondi","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"102828","DOI":"10.1016\/j.ebiom.2020.102828","article-title":"Oncolytic virotherapy meets the human organoid technology for pancreatic cancers","volume":"57","author":"Fiorini","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e1571390","DOI":"10.1080\/2162402X.2019.1571390","article-title":"Triple threat to cancer: Rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer","volume":"25","author":"Porter","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40425-017-0294-6","article-title":"Prospects for combined use of oncolytic viruses and CAR T-cells","volume":"5","author":"Ajina","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Woller, N., Gurlevik, E., Ureche, C.I., Schumacher, A., and Kuhnel, F. (2014). Oncolytic viruses as anticancer vaccines. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00188"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"eaao1641","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Roy","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e004462","DOI":"10.1136\/jitc-2021-004462","article-title":"The use of oncolytic virotherapy in the neoadjuvant setting","volume":"10","author":"Thomas","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/4\/461\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:30:13Z","timestamp":1776076213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/4\/461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":224,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["v18040461"],"URL":"https:\/\/doi.org\/10.3390\/v18040461","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}